Heat Biologics (HTBX) : Traders are bullish on Heat Biologics (HTBX) as it has outperformed the S&P 500 by a wide margin of 133.82% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 24.36%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 24.43% in the last 1 week, and is up 136.23% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 57.56% and the 50-Day Moving Average is 102.53%. Heat Biologics (NASDAQ:HTBX): On Fridays trading session , Opening price of the stock was $1.68 with an intraday high of $1.71. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $1.52. However, the stock managed to close at $1.63, a loss of 1.81% for the day. On the previous day, the stock had closed at $1.66. The total traded volume of the day was 786,788 shares.
The company Insiders own 22.8% of Heat Biologics shares according to the proxy statements. Institutional Investors own 15.78% of Heat Biologics shares. During last six month period, the net percent change held by insiders has seen a change of 1801.44%. Also, Roth Capital initiates coverage on Heat Biologics (NASDAQ:HTBX). In the latest research report, Roth Capital announces the target price to $2.75 per share. According to the latest information available, the shares are now rated Buy by the analysts at the agency. The rating by the firm was issued on June 20, 2016.
Heat Biologics, Inc. is a biopharmaceutical company. The Company is engaged in developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers and infectious diseases. The Company has two product candidates, which include HS-110 and HS-410 that are being evaluated in Phase II clinical trials for non-small cell lung cancer and bladder cancer, respectively. Its ImPACT Immune Pan Antigen Cytotoxic Therapy has been designed to deliver live, genetically-modified, irradiated human cells, which secrete a spectrum of disease-associated antigens together with a potent immune response stimulator called gp96. In cancer patients its ImPACT therapy generates anti-cancer immune responses by mobilizing and activating cytotoxic killer T cells that target multiple cancer antigens, thus harnessing a patients own immune system to fight cancer. Its ImPACT therapeutic vaccines do not require custom manufacturing.